FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Imp ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback